Latest Regulatory Milestones News

Newmont delivered solid second quarter 2026 results, generating $2.2 billion net income and record $2.2 billion free cash flow despite production setbacks at Cadia. The gold miner remains on track to meet full-year guidance while returning $1.9 billion to shareholders through dividends and buybacks.

Nelson Resources has kicked off underground drilling at its high-grade Orleans Mine while advancing rehabilitation at Great Western Mine and securing a strategic tungsten property adjacent to a major US project. Exploration spending reached $794k, supported by a $2.1 million cash buffer.

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.

Latitude 66 has locked in critical exploration permits for its high-grade KSB Project in Finland, enabling an accelerated development phase including drilling and advanced studies.

Caravel Minerals has advanced its Caravel Copper Project DFS with a 48% increase in Proven Ore Reserves and secured $15 million in new royalty funding from Regal Royalty Fund, while extending key regulatory timelines.

Flynn Gold has secured a key regulatory milestone by registering Mining Lease Application 6M/2026 over part of its Golden Ridge Project in northeast Tasmania, enabling accelerated development including resource drilling and environmental studies.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Coda Minerals has cleared a key regulatory hurdle for its Elizabeth Creek Copper-Silver Project with the formal gazettal of its Scoping Report, setting a clear pathway for mining lease approval and reducing project uncertainty.

AFT Pharmaceuticals secures tentative FDA approval for Scomara cream to treat rare facial tumours but faces a US launch delay due to orphan drug exclusivity. The approval bolsters prospects in other markets where AFT expects competitive advantages.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Vysarn Limited reported a record FY26 with NPBT of $20.9 million and operational revenue of $140.1 million, while completing the $50 million NewGround acquisition that boosts pro forma EPS by 26.7%.

Ausgold Limited has cleared significant regulatory hurdles for its Katanning Gold Project, with Western Australia’s EPA approving the Environmental Review Document for public release and three new mining leases granted, paving the way for a final investment decision by late 2026.